NLS Pharmaceutics (NLS Pharmaceutics) EV-to-EBIT : -0.36 (As of May. 17, 2024)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NLS Pharmaceutics's Enterprise Value is $5.47 Mil. NLS Pharmaceutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.38 Mil. Therefore, NLS Pharmaceutics's EV-to-EBIT for today is -0.36.

The historical rank and industry rank for NLS Pharmaceutics's EV-to-EBIT or its related term are showing as below:

NLSP' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.56 Med: 0 Max: 0
Current: -0.34

NLSP's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs NLSP: -0.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NLS Pharmaceutics's Enterprise Value for the quarter that ended in Jun. 2023 was $34.02 Mil. NLS Pharmaceutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.38 Mil. NLS Pharmaceutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -45.20%.

NLS Pharmaceutics EV-to-EBIT Historical Data

The historical data trend for NLS Pharmaceutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics EV-to-EBIT Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-1.06

-2.01

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial							-	-1.06	-	-2.01	-

Competitive Comparison of NLS Pharmaceutics's EV-to-EBIT

For the Biotechnology subindustry, NLS Pharmaceutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NLS Pharmaceutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's EV-to-EBIT falls into.

NLS Pharmaceutics EV-to-EBIT Calculation

NLS Pharmaceutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	5.472	/	-15.376
	=	-0.36

NLS Pharmaceutics's current Enterprise Value is $5.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NLS Pharmaceutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.38 Mil.

NLS Pharmaceutics (NAS:NLSP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NLS Pharmaceutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	-15.376	/	34.02079
	=	-45.20 %

NLS Pharmaceutics's Enterprise Value for the quarter that ended in Jun. 2023 was $34.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NLS Pharmaceutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.38 Mil.

NLS Pharmaceutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.